Mansi Shah
@MansiShahMD
Followers
296
Following
576
Media
14
Statuses
255
Joined November 2009
More options for patients with myeloma=increased access! Low CRS and minimal step up doses with linvo!
🌟 LINKER-MM1 Study: Linvoseltamab showed prolonged efficacy and safety in high-risk relapsed or refractory multiple #myeloma. 📝 Read more from the phase 2 expansion cohort study led by @MansiShahMD of @RutgersCancer/@RWJBarnabas. ➡️ https://t.co/19y1dylMnT
0
3
10
🚨Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort Congrats to @HadidiSamer @MansiShahMD: 1/🧵 New data on bispecific antibodies (BsAbs) in CNS multiple myeloma (CNS-MM) — a rare, aggressive manifestation of MM with historically poor
2
8
21
Great #MMsm thread about excellent @BrJHaem article re: bsAbs for CNS myeloma - @MansiShahMD @HiraSMian @HadidiSamer Part of why publishing RW data are so important: easy for insurers to ignore my #MMsm training or anecdotes, but harder to ignore a peer-reviewed publication!
@HiraSMian Absolutely! It was inspired by several initial payor denials I received when trying to use bsabs for patients with cns involvement of multiple myeloma citing lack of data. Now we have it!
0
4
13
Check our recent work: Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort #mmsm @MeeraMohanMD @MansiShahMD @BrJHaem ➡️ https://t.co/cwNggtSmB8 ✔️ 100% CNS response (n=6 evaluable) ✔️ 2 pts responded before CNS-directed therapy ✔️ No grade
3
13
37
Our multicenter series shows bispecific antibodies may offer meaningful CNS activity with manageable safety. Led by fellow Alex N! @MeeraMohanMD @HadidiSamer
https://t.co/Au5P6ee8Um
#CNSMyeloma #mmsm @RutgersCancer @RWJBarnabas
onlinelibrary.wiley.com
Click on the article title to read more.
4
16
50
We are talking about amyloidosis today with cardiology, pathology, neurology and heme-onc colleagues! @RutgersCancer @RWJBarnabas #ALAmyloid #ATTR
0
3
23
We want to share this important toxicity profile of GPRC5D BisAb- Talquetamab. GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series https://t.co/Y4f4krHEJQ Full link- https://t.co/CDKAxwD5J3
7
31
69
The fascinating story of Thalidomide: how this most notorious drug on the planet, banned in the 1960s, made an incredible comeback and revolutionized the treatment of myeloma. I will also highlight one person whose role is not recognized: Without Dr. Leif Bergsagel there will
18
177
640
Carfilzomib for myeloma: I don’t recommend any more than 56 mg/m2 once a week Our study results show that higher doses do not offer more benefit. @sharlenedong @RahulBanerjeeMD @GKaurMD @AimazAfrough @JanakiramMurali @BloodCancerJnl
https://t.co/4yslrFfbAm
nature.com
Blood Cancer Journal - Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis
5
46
145
#Myeloma Paper of the Day: Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in myeloma includes higher risk of prolonged transfusion dependence for both pRBC and G-CSF us, as well as higher thrombopoietin receptor agonist use: https://t.co/4jY40zcFEt.
#mmsm
1
15
33
RW #MMsm data in action! Congrats @MeeraMohanMD @FarheenChunara on @BloodCancerJnl publication: tec & tal in 🇺🇸 myeloma patients. Bottom line: some bsAb trials still say Q1W x6 months before de-escalating to ≤Q2W. In real life: most of us don't wait this long, nor should we!
https://t.co/gVAM7WoEBL RW dosing patterns D0-2-4 SUD schedule was commonly used for Tec and Tal. Second SUD used in ~0.7% of cases. Long-term dosing- 1/3 of Tec doses after 3M were Q2W, and 13% were Q4W after 6M. Tal was mostly administered Q2W @MCWCancerCenter #mmsm
0
6
20
https://t.co/gVAM7WoEBL RW dosing patterns D0-2-4 SUD schedule was commonly used for Tec and Tal. Second SUD used in ~0.7% of cases. Long-term dosing- 1/3 of Tec doses after 3M were Q2W, and 13% were Q4W after 6M. Tal was mostly administered Q2W @MCWCancerCenter #mmsm
nature.com
Blood Cancer Journal - Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients
1
11
29
#DAVAWhistler great presentation by #mansishah regarding using “pocket dex” as the first step for CRS management with bispecifics in myeloma #MMsm. Great work by @thisisJamesD and colleagues!
2
4
15
Dr. @MansiShahMD from @RutgersCancer discusses key biohacks for #Bispecifics in #MultipleMyeloma: âś… Hybrid inpatient-outpatient models âś… Community training & patient selection âś… Optimized step-up dosing & real-world insights for enhanced safety and access #DAVAWhistler
0
5
13
At the #DAVAWhistler summit, @MansiShahMD from @RutgersCancer discusses Linvoseltamab, a BCMAxCD3 bispecific antibody, with updated results from the LINKER-MM1 trial. The presentation includes 21.3 months median follow-up data on efficacy and safety in R/R MM. #Hematology
0
3
8
Dr. @MansiShahMD from @RutgersCancer highlights Venetoclax potential for t(11;14) MM, showing ORR & PFS results in trials like BELLINI & CANOVA. #Oncology #Hematology #DAVAWhistler
0
4
8
Infections With Bispecific Antibodies for Myeloma: Where Do We Stand Now? https://t.co/WPt21DXrBr
@DrPMPGI @UdayYanamandra @MCWCancerCenter #mmsm
dailynews.ascopubs.org
Bispecific antibody therapies are highly active treatment options for myeloma. However, these drugs are uniquely associated with an increased risk of infection, including grade 3 or higher infection...
1
12
34
CD4+ T-cell lymphoma harboring a CAR vector Integration in TP53 after treatment with cilta-cel in a patient with RRMM #mmsm #bmtsm @NEJM
nejm.org
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o...
0
3
15
Independent physicians aren’t “providers.” They’re doctors or physicians. The only ones who call them “providers” are insurers and bureaucrats who want them interchangeable with a chatbot or a massage therapist. Stop using their language. #healthcare
58
88
733
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma - BioSpace!! #mmsm
biospace.com
0
5
13